Partnering with Innovative Healthcare Companies
Venture Capital
Our venture capital practice targets companies with compelling technologies or competitive advantages which address unmet needs in large markets. This is where a minority of our capital is deployd for the most recent funds. We define these opportunities as ones with the following characteristics: 1) Essex Woodlands is either the early stage lead investor or the “last money in”, 2) Essex Woodlands is the largest institutional shareholder, and 3) the company is an attractive acquisition target due to the compelling technology and/or competitive advantages.
Beyond providing capital, we also support the earliest stages of a company’s formation, assisting management teams on strategy development, recruiting key personnel and identifying capital to advance their clinical, technological or market objectives. Later in a company’s evolution, we are especially suited to helping our partners commercialize their products and build a sustainable business.
Case Study
Emerging biopharmaceutical company which develops novel products to address unmet medical needs
Essex Woodlands made our investment in Ception based upon our belief that Ception’s antibody against interleukin 5 (anti-IL-5mAb) would eventually become both a clinical and commercial success. …
Learn More